Pyroglutamic Acidosis: A Rare and Underdiagnosed Cause of High Anion Gap Metabolic Acidosis

Brigid Hallinan DO  
Lehigh Valley Health Network

Tina M. Casey DO  
Lehigh Valley Health Network, Tina_M.Casey@lvhn.org

Matthew McCambridge MD  
Lehigh Valley Health Network, Matthew.Mccambridge@lvhn.org

Follow this and additional works at: http://scholarlyworks.lvhn.org/medicine

Part of the Medical Sciences Commons

Published In/Presented At

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Introduction:
High anion gap metabolic acidosis (HAGMA) is a common metabolic disorder encountered in the ICU setting. A likely underdiagnosed cause of HAGMA is pyroglutamic acidosis (5-oxoprolinuria), a condition caused by a defect in the gamma-glutamyl cycle. Initially recognized as the result of a hereditary enzyme deficiency leading to significant metabolic abnormalities early in life, an increasing number of pyroglutamic acidosis cases have been reported in previously unaffected adults due to an acquired defect in the gamma-glutamyl cycle, nearly all associated with acetaminophen use. We present the case of a patient who developed severe pyroglutamic acidosis while on chronic acetaminophen therapy.

Case Presentation:
History: A 58-year-old Caucasian female presented to the emergency department complaining of a three-day history of rapidly progressive dyspnea. On arrival, she was afebrile, alert, and oriented to person, place, and time. Vital signs on admission were as follows: 97.4°F, blood pressure 142/72, pulse 143, respirations 28, and oxygen saturation 99% on room air. Physical examination simply revealed a well-nourished but acutely ill-appearing female in mild respiratory distress. Review of systems was positive for poor oral intake, headache, chest tightness, and several episodes of vomiting. Past medical history included hypertension, peptic ulcer disease, chronic low back pain, depression, and anxiety. She denied any known history of renal disease. Medications included omeprazole, duloxetine, aripiprazole, lorazepam, amitriptyline, melatonin, hydrocodone/acetaminophen and acetaminophen. She noted that she had been recently taking a significantly increased amount of acetaminophen for pain. The patient cited a 40-pack-year smoking history and quit ten years ago. She denied ingestion of ethanol, methanol, paradylethly, ethylene glycol, or any illicit substances.

Physical Exam: Vital signs on admission were as follows: 97.4°F, blood pressure 142/72, pulse 143, respirations 28, and oxygen saturation 99% on room air. Physical examination simply revealed a well-nourished but acutely ill-appearing female in mild respiratory distress.

Diagnostic Data: Initial laboratory studies (Table 1) revealed a high anion gap metabolic acidosis with pH 7.02, HCO₃⁻ 40-60 mg/dL, negative ethylene glycol, and acetaminophen. Urine analysis was negative for elevated lactate or salicylate levels, ketones, urates, or evidence of methanol or ethylene glycol poisoning. The urine organic acid screen revealed a markedly elevated level of pyroglutamic acid.

Clinical Course: Based on the patient’s laboratory studies and clinical findings, she was diagnosed with pyroglutamic acidosis associated with acetaminophen ingestion. Her acidosis resolved with discontinuation of all acetaminophen-containing compounds, volume resuscitation, and administration of intravenous sodium bicarbonate. The patient rapidly improved with treatment and was discharged home in stable condition on the fourth day of hospitalization with instructions to discontinue acetaminophen use indefinitely.

Discussion:
Pathogenesis: Pyroglutamic acidosis occurs as a result of a defect in the gamma-glutamyl cycle. This cycle is composed of a series of enzymatic reactions that ultimately leads to the production of the tripeptide glutathione, which serves an important role in many cells of the body- scavenging free oxygen radicals, drug detoxification, and amino acid metabolism (Figure 1). When normal or high levels of glutathione are present, the production of its smaller molecules is inhibited by negative feedback on the enzyme gamma-glutamylcystein synthetase. With chronic acetaminophen use, however, glutathione stores can be depleted, leading to up-regulation of gamma-glutamylcystein synthetase and increased production of gamma-glutamylcysteine. This molecule is normally then converted to glutathione by gluta- thione synthetase. However, with significant elevation in gamma-glutamylcysteine levels, conversion to glutathione becomes the rate-limiting step and some gamma-glutamylcysteine enters the secondary metabolic pathway to be converted into "pyroproline, a cyclic peptide of a gamma-glutamyl residue". It is the build-up of this molecule that leads to severe high anion gap metabolic acidosis.

Risk Factors: There are several risk factors that have been implicated in the development of pyroglutamic acidosis, particularly when combined with use of acetaminophen. These include sepsis, alcohol abuse, renal failure, hepatic dysfunction, malnutrition, premature, pregnancy, severe burns, Stevens-Johnson syndrome, uvea cycle disorders, hawkinsnta, homocysteina, and artificial diets. Certain medications, including netilmicin, flucloxacillin, and vigabatrin, have also been linked to the disorder. The reason for our patient’s sudden development of severe metabolic acidosis after many years of being on chronic acetaminophen therapy was unclear but may have been precipitated by an increase in acetaminophen intake in the setting of acute malnutrition.

Diagnosis: Diagnosis is made by recognition of high anion gap metabolic acidosis not explained by another etiology and either positive gas chromatography or detection of an elevated pyroglutamic acid level on a urine organic acid screen level or acetaminophen level, as may be checked in order to rule out overdose, however, a low or undetectable acetaminophen level does not rule out pyroglutamic acidosis, as most cases do occur in patients taking therapeutic doses of acetaminophen, with its possible therapeutic benefit in repleting glutathione stores and its low potential for toxicity, its use as an adjunctive measure does not seem unreasonable.

Treatment: Initial management involves discontinuation of all acetaminophen-containing medications, reversal of severe metabolic acidosis by correction of metabolic acidosis, and supplementation of intravenous fluids and treatment of any co-morbid conditions. Intravenous N-acetylcysteine, the standard therapy for acetaminophen poisoning, may be of some benefit in the management of increased pyroglutamic acidosis. Treatment has been well studied. However, with its possible therapeutic benefit in repleting glutathione stores and its low potential for toxicity, its use as an adjunctive measure does not seem unreasonable.

Conclusion: The diagnosis of pyroglutamic acidosis should be considered in the differential for any patient presenting with high anion gap metabolic acidosis, particularly if there is a history of recent acetaminophen use. Increased awareness and prompt recognition of this condition by physicians can prevent fatal outcomes and recurrences in susceptible patients.

References: